Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects

Purpose Fedratinib is an orally administered Janus kinase 2-selective inhibitor that is indicated for the treatment of adult patients with intermediate-2 or high-risk myelofibrosis in the United States. Fedratinib is metabolized by multiple cytochrome P450s (CYPs) in vitro, with the predominant cont...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancer chemotherapy and pharmacology Ročník 85; číslo 5; s. 899 - 906
Hlavní autoři:	Ogasawara, Ken, Xu, Christine, Kanamaluru, Vanaja, Palmisano, Maria, Krishna, Gopal
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2020 Springer Nature B.V
Témata:	Adult Antifungal agents Area Under Curve Cancer Research Cohort Studies Cross-Over Studies Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics Dose-Response Relationship, Drug Drug Administration Schedule Drug Monitoring - methods Drug Synergism Enzyme inhibitors Healthy Volunteers Humans Janus kinase Janus kinase 2 Janus Kinase 2 - antagonists & inhibitors Ketoconazole Ketoconazole - pharmacokinetics Male Medicine Medicine & Public Health Myelofibrosis Oncology Oral administration Original Article Pharmacology/Toxicology Primary Myelofibrosis - drug therapy Pyrrolidines - pharmacokinetics Sulfonamides - pharmacokinetics Treatment Outcome Fedratinib Ketoconazole CYP3A4 Pharmacokinetics Drug–drug interaction
ISSN:	0344-5704, 1432-0843, 1432-0843
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!